Clinical Trial Update: Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody [Phase 2]

View source ↗

Summary

Phase 2 study evaluating AZD5148 monoclonal antibody to prevent recurrent Clostridioides difficile infection is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• AZD5148 monoclonal antibody (AZD5148)

Snippet

Sponsor: AstraZeneca | Conditions: Clostridioides Difficile Infection | Phase 2 | Status: RECRUITING